Nastech Announces Positive Phase 1 Clinical Results Of Insulin Nasal Spray Compared To Exubera(R) Inhalation Powder And NovoLog(C) Insulin

Thu, 07 Dec 2006 02:00 PM EST

... Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today announced results from a placebo controlled, dose-escalation, cross-over Phase 1 study of Nastech's proprietary insulin nasal spray formulations, NovoLog insulin aspart (rDNA origin) injection and Exubera (insulin human [rDNA origin]) Inhalation Powder in healthy subjects. [click link for full article] ...